S

SWK Holdings Corp
NASDAQ:SWKH

Watchlist Manager
SWK Holdings Corp
NASDAQ:SWKH
Watchlist
Price: 15.89 USD 4.2% Market Closed
Market Cap: 196.4m USD
Have any thoughts about
SWK Holdings Corp?
Write Note

SWK Holdings Corp
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SWK Holdings Corp
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
S
SWK Holdings Corp
NASDAQ:SWKH
Revenue
$53.6m
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
14%
LM Funding America Inc
NASDAQ:LMFA
Revenue
$17.8m
CAGR 3-Years
6%
CAGR 5-Years
46%
CAGR 10-Years
N/A
A-Mark Precious Metals Inc
NASDAQ:AMRK
Revenue
$9.9B
CAGR 3-Years
9%
CAGR 5-Years
16%
CAGR 10-Years
5%
FlexShopper Inc
NASDAQ:FPAY
Revenue
$134.6m
CAGR 3-Years
3%
CAGR 5-Years
10%
CAGR 10-Years
50%
California First Leasing Corp
OTC:CFNB
Revenue
$47.9m
CAGR 3-Years
-2%
CAGR 5-Years
26%
CAGR 10-Years
N/A
S
Standard Premium Finance Holdings Inc
OTC:SPFX
Revenue
$9.7m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

SWK Holdings Corp
Glance View

Market Cap
194.9m USD
Industry
Financial Services

SWK Holdings Corp. is engaged in the business of financial and asset management in the field of pharmaceutical. The company is headquartered in Dallas, Texas and currently employs 35 full-time employees. The firm is focused on providing various capital solutions to a range of life science companies, institutions and inventors. The firm operates through two segments: Finance Receivables and Pharmaceutical Development. Its Finance Receivables segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. In addition, through its wholly owned subsidiary, SWK Advisors LLC, it provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. Through its subsidiary, Enteris BioPharma, Inc., its Pharmaceutical Development segment offers formulation solutions built around its oral drug delivery technology, the Peptelligence platform.

SWKH Intrinsic Value
18 USD
Undervaluation 12%
Intrinsic Value
Price
S

See Also

What is SWK Holdings Corp's Revenue?
Revenue
53.6m USD

Based on the financial report for Sep 30, 2024, SWK Holdings Corp's Revenue amounts to 53.6m USD.

What is SWK Holdings Corp's Revenue growth rate?
Revenue CAGR 10Y
14%

Over the last year, the Revenue growth was 42%. The average annual Revenue growth rates for SWK Holdings Corp have been 1% over the past three years , 14% over the past five years , and 14% over the past ten years .

Back to Top